Besancon University Hospital Center
- Address
- 3 Boulevard Alexandre Fleming, 25000 Besançon, France
Cardiovascular Diseases
At Besancon University Hospital Center, research in cardiovascular diseases focuses on preventing serious events such as ischemic stroke and atherosclerotic cardiovascular disease. The trials are designed to assess whether new approaches can better reduce future heart and brain complications in people at elevated risk.
- Prevention of major adverse cardiovascular events in high-risk patients
- Reducing recurrent ischemic stroke after a recent stroke or high-risk transient ischemic attack
- Evaluating new treatments for primary prevention of ASCVD
These studies aim to improve long-term protection against clot-related vascular events and support better preventive care in everyday practice.
Neoplasms
The oncology research program at the Service de d'Oncologie-Radiothérapie includes trials in acute myeloid leukemia and prostate cancer. The main goal is to find more effective ways to deepen remission, strengthen treatment response, and improve outcomes for patients with aggressive or high-risk cancers.
- Improving remission rates in acute myeloid leukemia
- Testing better treatment strategies for high-risk localized or locally advanced prostate cancer
- Supporting more precise cancer care through treatment-response evaluation
These studies reflect a strong focus on both blood cancers and solid tumors, with an emphasis on better disease control and longer-lasting benefit.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 34 therapeutic areas and 15 of 575 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 548 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 109 by active trials.
lock +108 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +69 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Besancon University Hospital Center
lock Showing 1 of 444 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 575 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paclitaxel | 47 | Unknown | 2016-10-17 | 2026-03-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.